Literature DB >> 25270369

Mild Lafora disease: clinical, neurophysiologic, and genetic findings.

Edoardo Ferlazzo1, Laura Canafoglia, Roberto Michelucci, Antonio Gambardella, Elena Gennaro, Elena Pasini, Patrizia Riguzzi, Rosaria Plasmati, Lilia Volpi, Angelo Labate, Sara Gasparini, Flavio Villani, Marina Casazza, Maurizio Viri, Federico Zara, Berge A Minassian, Julie Turnbull, Jose M Serratosa, Rosa Guerrero-López, Silvana Franceschetti, Umberto Aguglia.   

Abstract

We report clinical, neurophysiologic, and genetic features of an Italian series of patients with Lafora disease (LD) to identify distinguishing features of those with a slowly progressive course. Twenty-three patients with LD (17 female; 6 male) were recruited. Mean age (± SD) at the disease onset was 14.5 ± 3.9 years and mean follow-up duration was 13.2 ± 8.0 years. NHLRC1 mutations were detected in 18 patients; EPM2A mutations were identified in 5. Patients who maintained >10 years gait autonomy were labeled as "mild" and were compared with the remaining LD patients with a typical course. Six of 23 patients were mild and presented significantly delay in the age at onset, lower neurologic disability score at 4 years after the onset, less severe seizure phenotype, lower probability of showing both photoparoxysmal response on electroencephalography (EEG) and giant somatosensory evoked potentials, as compared to patients with typical LD. However, in both mild and typical LD patients, EEG showed disorganization of background activity and frequent epileptiform abnormalities. Mild LD patients had NHLRC1 mutations and five of six carried homozygous or compound heterozygous D146N mutation. This mutation was found in none of the patients with typical LD. The occurrence of specific NHLRC1 mutations in patients with mild LD should be taken into account in clinical practice for appropriate management and counseling. Wiley Periodicals, Inc.
© 2014 International League Against Epilepsy.

Entities:  

Keywords:  Dementia; EEG; Mild; Progressive myoclonus epilepsy; Slowly progressive

Mesh:

Substances:

Year:  2014        PMID: 25270369     DOI: 10.1111/epi.12806

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  12 in total

Review 1.  The genetics of the epilepsies.

Authors:  Christelle M El Achkar; Heather E Olson; Annapurna Poduri; Phillip L Pearl
Journal:  Curr Neurol Neurosci Rep       Date:  2015-07       Impact factor: 5.081

Review 2.  Lafora disease: from genotype to phenotype.

Authors:  Rashmi Parihar; Anupama Rai; Subramaniam Ganesh
Journal:  J Genet       Date:  2018-07       Impact factor: 1.166

Review 3.  Lafora disease - from pathogenesis to treatment strategies.

Authors:  Felix Nitschke; Saija J Ahonen; Silvia Nitschke; Sharmistha Mitra; Berge A Minassian
Journal:  Nat Rev Neurol       Date:  2018-10       Impact factor: 42.937

4.  A novel EPM2A mutation yields a slow progression form of Lafora disease.

Authors:  Maria Adelaida Garcia-Gimeno; Pilar Natalia Rodilla-Ramirez; Rosa Viana; Xavier Salas-Puig; M Kathryn Brewer; Matthew S Gentry; Pascual Sanz
Journal:  Epilepsy Res       Date:  2018-07-21       Impact factor: 3.045

5.  Italian cohort of Lafora disease: Clinical features, disease evolution, and genotype-phenotype correlations.

Authors:  Antonella Riva; Alessandro Orsini; Marcello Scala; Vittoria Taramasso; Laura Canafoglia; Giuseppe d'Orsi; Maria Teresa Di Claudio; Carlo Avolio; Alfredo D'Aniello; Maurizio Elia; Silvana Franceschetti; Giancarlo Di Gennaro; Francesca Bisulli; Paolo Tinuper; Maria Tappatà; Antonino Romeo; Elena Freri; Carla Marini; Cinzia Costa; Vito Sofia; Edoardo Ferlazzo; Adriana Magaudda; Pierangelo Veggiotti; Elena Gennaro; Angela Pistorio; Carlo Minetti; Amedeo Bianchi; Salvatore Striano; Roberto Michelucci; Federico Zara; Berge Arakel Minassian; Pasquale Striano
Journal:  J Neurol Sci       Date:  2021-03-20       Impact factor: 3.181

6.  Natural history of Lafora disease: a prognostic systematic review and individual participant data meta-analysis.

Authors:  Luca Vignatelli; Francesca Bisulli; Federica Pondrelli; Lorenzo Muccioli; Laura Licchetta; Barbara Mostacci; Corrado Zenesini; Paolo Tinuper
Journal:  Orphanet J Rare Dis       Date:  2021-08-16       Impact factor: 4.123

7.  Genotypes and phenotypes of patients with Lafora disease living in Germany.

Authors:  David Brenner; Tobias Baumgartner; Sarah von Spiczak; Jan Lewerenz; Roger Weis; Anja Grimmer; Petra Gaspirova; Claudia D Wurster; Wolfram S Kunz; Jan Wagner; Berge A Minassian; Christian E Elger; Albert C Ludolph; Saskia Biskup; Dennis Döcker
Journal:  Neurol Res Pract       Date:  2019-11-12

8.  Treatment with metformin in twelve patients with Lafora disease.

Authors:  Francesca Bisulli; Lorenzo Muccioli; Giuseppe d'Orsi; Laura Canafoglia; Elena Freri; Laura Licchetta; Barbara Mostacci; Patrizia Riguzzi; Federica Pondrelli; Carlo Avolio; Tommaso Martino; Roberto Michelucci; Paolo Tinuper
Journal:  Orphanet J Rare Dis       Date:  2019-06-21       Impact factor: 4.123

Review 9.  Genetics of Lafora progressive myoclonic epilepsy: current perspectives.

Authors:  Miljana Kecmanović; Milica Keckarević-Marković; Dušan Keckarević; Galina Stevanović; Nebojša Jović; Stanka Romac
Journal:  Appl Clin Genet       Date:  2016-05-02

10.  Unusual Course of Lafora Disease.

Authors:  Rodi Zutt; Gea Drost; Yvonne J Vos; Jan Willem Elting; Irene Miedema; Marina A J Tijssen; Oebele F Brouwer; Bauke M de Jong
Journal:  Epilepsia Open       Date:  2016-08-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.